Hip

Study into Cancer risk in the first seven years after Metal-on-Metal Hip Replacement compared with other bearings and general population: linkage study between the National Joint Registry of England and Wales and hospital episode statistics.

UK MHRA singles out specific combinations of hip/stem for attention, this alert proving the value of the data in England and Wales Joint Registry.

It looks like it’s invitation only for the FDA panel review meeting to be held in June, at which experts will discuss all aspects of the Metal-on-Metal hip disaster.

Let’s face facts. Medical device regulation is by definition imperfect, however much we fiddle with it. The world’s toughest regulator is apparently a pussycat allowing devices onto the market without such as a by-your-leave. If you believe the so-well-informed media.

Millennium Research Group predict modest growth in large joint market as price pressure waters down procedure growth.

Snappy dressers these new powertools from Stryker, offering a range of “enhancements” including quieter operation, better battery life and heightened torque.

Did you hear the one about the company that thought it had a winner on its hands by developing its own version of an increasingly popular type of hip replacement?

MHRA fights back against media claims that it needs to “recover its grip” over medical device regulation in light of the metal-on-metal hip situation.

MHRA provides advice on follow-up systems for all-metal hips to include testing of all patients with large diameter femoral component and all ASR hips.

Will we ever see through the fog in the DePuy ASR case? Internal emails now suggest product performance was a consideration in stopping the PMA and ultimate product withdrawal.

It’s a bit of a journalistic open goal when BBC publishes on the fate of “cremated” prostheses at the same time as we’re wondering about the fate of the Costa Concordia. Sounds like they might both end up as wind turbines.

Johnson & Johnson DePuy sees fit to respond to New York Times article it claims to contain untruths regarding how it behaved during the all-metal implant situation.

New research may pave the way for all-metal hip prostheses to rise phoenix-like from the ashes.

A new article in the New York times suggests J&J DePuy were wrong in continuing to sell product overseas after FDA raised concerns. If that happened every time FDA demanded more clinicals we might as well harmonise.

DePuy Orthopaedics unveils advancements in orthopaedic treatment at AAOS. Focus is on Clinical and Economic Value, Procedural Efficiency, Personalization.

Update from TeDan surgical on CE status of its new MIS Hip Retractor.